当前位置: 首页 >> 检索结果
921. Remote monitoring of patients with rheumatoid arthritis in a low disease activity state: a mixed methods evaluation across six hospitals in London, UK.
作者: Kathryn Watson.;Helen Sheldon.;Elena Pallari.;Nikita Arumalla.;Rachel R Olive.;Olga Boiko.;Camille Aznar.;Emma-Jayne Adams.;Ailsa Bosworth.;Len Demetriou.;Melanie Martin.;Mary-Ann Palmer.;Polly Sinclair.;Emily J Smith.;Nick Sevdalis.;Andrew Walker.;Toby Garrood.
来源: Rheumatology (Oxford). 2024年63卷10期2721-2733页
This study evaluated the scale-up of a remote monitoring service, capturing monthly Rheumatoid Arthritis Impact of Disease scores and patient-generated text messages, for patients with rheumatoid arthritis (RA; in remission or with low disease activity) attending routine outpatient clinics across six hospitals. We explored patients and staff experiences and implementation outcomes.
922. Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up.
作者: Ioannis Parodis.;Thomas Haugli-Stephens.;Annica Dominicus.;Daniel Eek.;Christopher Sjöwall.
来源: Rheumatology (Oxford). 2025年64卷2期639-647页
Beyond prevention of organ damage, treatment goals in SLE include optimization of health-related quality of life (HRQoL). The Lupus Low Disease Activity State (LLDAS) has received increasing attention as a goal whenever remission cannot be achieved. How SLE disease activity, organ damage and LLDAS attainment relate to patient-reported outcomes (PROs) is not fully explored, which formed the scope of this investigation.
923. Impact on patient outcomes of spondyloarthritis-inflammatory bowel disease multi-disciplinary meetings.
作者: Sarah Sayers.;Danielle Lam.;Qutab Shah.;Jobie Evans.;Miles Parkes.;Carmel Stober.;Joanne Rimmer.;Gavin Clunie.;Tania-Elena Gudu.;Denise Rosembert.;Sreedhar Subramanian.;Stephanie Brookes-Jones.;Stephen Moss.;Tim Raine.;Deepak Jadon.
来源: Rheumatology (Oxford). 2025年64卷2期815-820页
To assess the impact on patient outcomes of the spondyloarthritis (SpA) and inflammatory bowel disease (IBD) multidisciplinary team (MDT) meetings in a large university hospital.
924. Participation in cardiovascular screening consultations, the who, when and why - A cohort study on patients with rheumatoid arthritis.
作者: Julie Katrine Karstensen.;Ann Bremander.;Jeanette Reffstrup Christensen.;Jette Primdahl.
来源: BMC Rheumatol. 2024年8卷1期8页
In accordance with the EULAR recommendations, the Danish Hospital for Rheumatic Diseases have systematically invited patients with rheumatoid arthritis (RA) to cardiovascular (CV) risk assessment since 2011. Patients with high risk are invited to a follow-up screening after one year. To optimize the screening and tailor it to individual needs, information about who accepts vs. declines follow-up is needed. Thus, the aim of this study was to explore participation in systematic CV risk assessment among patients with RA. Furthermore, to explore differences between patients with low vs. high risk, and between patients with high risk who accept vs. decline follow-up.
925. Global, regional, and national burden of neck pain, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.
Neck pain is a highly prevalent condition that leads to considerable pain, disability, and economic cost. We present the most current estimates of neck pain prevalence and years lived with disability (YLDs) from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) by age, sex, and location, with forecasted prevalence to 2050.
927. An assessment of cardiovascular disease hospitalizations and disparities by race in patients with rheumatic disease hospitalizations in Alaska, 2015-2018.
There is an increased risk of cardiovascular disease in people with many rheumatic diseases. The primary objective of this study was to evaluate cardiovascular disease hospitalizations in Alaska for people with and without a rheumatic disease diagnosis and assess disparities by race, with a focus on Alaska Native and American Indian people.
928. Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis.
作者: Matthew James Sinclair Parker.;Adelle S Jee.;Dylan Hansen.;Susanna Proudman.;Peter Youssef.;Tony J Kenna.;Wendy Stevens.;Mandana Nikpour.;Joanne Sahhar.;Tamera J Corte.
来源: Rheumatology (Oxford). 2024年63卷11期2981-2988页
To investigate the prognostic utility of 28 serum biomarkers in systemic sclerosis (SSc), SSc-associated interstitial lung disease (SSc-ILD) and clinically relevant disease subgroups.
929. Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study.
作者: Céleste J T van der Togt.;Nathan den Broeder.;Marleen S Boonstra.;Aatke van der Maas.;Alfons A den Broeder.;Noortje van Herwaarden.
来源: Rheumatology (Oxford). 2025年64卷2期533-540页
The objective of this study was to investigate the safety and effectiveness of disease activity-guided dose optimization of TNF inhibitors in RA over 10 years.
930. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.
作者: Dennis McGonagle.;Arthur Kavanaugh.;Iain B McInnes.;Lars Erik Kristensen.;Joseph F Merola.;Bruce Strober.;Rebecca Bolce.;Jeffrey Lisse.;Jennifer Pustizzi.;Christophe Sapin.;Christopher Ritchlin.
来源: Rheumatology (Oxford). 2024年63卷11期3115-3123页
To assess the frequency of simultaneous distal interphalangeal (DIP) joint disease and adjacent nail psoriasis (finger unit) among patients with psoriatic arthritis (PsA) and compare the efficacy of the IL-17A antagonist ixekizumab (IXE) and the TNF-α inhibitor adalimumab (ADA).
932. Lung imaging patterns in connective tissue disease-associated interstitial lung disease impact prognosis and immunosuppression response.
作者: Boyang Zheng.;Daniel-Costin Marinescu.;Cameron J Hague.;Nestor L Muller.;Darra Murphy.;Andrew Churg.;Joanne L Wright.;Amna Al-Arnawoot.;Ana-Maria Bilawich.;Patrick Bourgouin.;Gerard Cox.;Celine Durand.;Tracy Elliot.;Jennifer Ellis.;Jolene H Fisher.;Derek Fladeland.;Amanda Grant-Orser.;Gillian C Goobie.;Zachary Guenther.;Ehsan Haider.;Nathan Hambly.;James Huynh.;Kerri A Johannson.;Geoffrey Karjala.;Nasreen Khalil.;Martin Kolb.;Jonathon Leipsic.;Stacey D Lok.;Sarah MacIsaac.;Micheal McInnis.;Helene Manganas.;Veronica Marcoux.;John Mayo.;Julie Morisset.;Ciaran Scallan.;Tony Sedlic.;Shane Shapera.;Kelly Sun.;Victoria Tan.;Alyson W Wong.;Christopher J Ryerson.
来源: Rheumatology (Oxford). 2024年63卷10期2734-2740页
Interstitial lung disease (ILD) in CTDs has highly variable morphology. We aimed to identify imaging features and their impact on ILD progression, mortality, and immunosuppression response.
933. Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement.
作者: Olof C B Vermeulen.;Elisabeth Brouwer.;Riemer H J A Slart.;Maria Sandovici.;Abraham Rutgers.;T Jeroen Hilterman.;Birgitta Hiddinga.;Sjoukje F Oosting.;Mathilde Jalving.;Albert H de Heij.;Daan G Knapen.;Geke A P Hospers.;Kornelis S M van der Geest.
来源: Rheumatology (Oxford). 2025年64卷2期771-779页
To compare clinical characteristics, imaging findings and treatment requirements of patients with immune checkpoint inhibitor-mediated polymyalgia rheumatica (ICI-PMR) and primary PMR.
934. Predictors of lack of response to methotrexate in juvenile idiopathic arthritis associated uveitis.
作者: Chiara Mapelli.;Elisabetta Miserocchi.;Marco Nassisi.;Gisella B Beretta.;Luca Marelli.;Gaia Leone.;Achille Marino.;Cecilia Chighizola.;Gilberto Cincinelli.;Teresa Giani.;Paolo Nucci.;Francesco Viola.;Giovanni Filocamo.;Francesca Minoia.; .
来源: Rheumatology (Oxford). 2025年64卷2期798-804页
To investigate clinical features associated with lack of response to MTX in juvenile idiopathic arthritis associated uveitis (JIA-U).
936. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.
作者: Fabrizio Cantini.;Antonio Marchesoni.;Lucia Novelli.;Giuliana Gualberti.;Francesca Marando.;Erin L McDearmon-Blondell.;Tianming Gao.;Dennis McGonagle.;Carlo Salvarani.
来源: Rheumatology (Oxford). 2024年63卷11期3146-3154页
To characterize the effect of upadacitinib 15 mg once daily (UPA15) on enthesitis in patients with PsA from the SELECT-PsA Phase 3 trials.
937. The information required by people with inflammatory arthritis when taking Methotrexate: a mixed-methods systematic review.
作者: Sarah J Logan.;Samantha Hider.;Julie Green.;Sarah J Ryan.
来源: Rheumatology (Oxford). 2024年63卷10期2615-2623页
This mixed-methods systematic review aimed to identify and synthesize knowledge of the characteristics, content, and preferred format of information to support people with inflammatory arthritis (IA) to take MTX.
938. Serum protein profiling reveals distinct patient clusters in giant cell arteritis.
作者: Flavia Zingg.;Fabio S Ryser.;Andrea D Gloor.;Christos Polysopoulos.;Peter M Villiger.;Britta Maurer.;Lisa Christ.
来源: Rheumatology (Oxford). 2024年63卷10期2887-2896页
We investigated the potential of serum proteins for distinguishing clinical and molecular subtypes in patients with GCA.
939. Seven-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls.
作者: Gerasimos Evangelatos.;Nikolaos Tentolouris.;Petros P Sfikakis.;Maria G Tektonidou.
来源: Rheumatology (Oxford). 2025年64卷2期836-841页
Patients with antiphospholipid syndrome (APS) carry a substantial burden of cardiovascular disease and subclinical atherosclerosis. We aimed to assess a 7-year follow-up atherosclerotic plaque progression in APS patients versus diabetes mellitus (DM) and healthy controls (HC).
940. Patient-reported outcome for physical function in idiopathic inflammatory myopathy.
作者: Shiri Keret.;Raisa Lomanto Silva.;Tanya Chandra.;Akanksha Sharma.;Siamak Moghadam-Kia.;Chester V Oddis.;Rohit Aggarwal.
来源: Rheumatology (Oxford). 2025年64卷2期763-770页
There is an unmet need to develop patient-reported outcomes measures for idiopathic inflammatory myopathies (IIM). We aimed to investigate the feasibility, compliance and psychometric properties of the National Institutes of Health's Patient-Reported Outcomes Measurement Information System (PROMIS) physical function-20 (PF-20) in a large US IIM population.
|